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ABSTRACT 
A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorized original biological medicinal 
product (reference medicinal product). A biosimilar demonstrates similarity to the reference biological product in terms of quality characteristics, 
biological activity, safety and efficacy based on a comprehensive comparability exercise. EMA (European Medicines Agency) was the first to 
introduce the guidelines for biosimilar approval, effective from June 2006. Biosimilar guideline was released in 2010 in Brazil and 2012 in India. 
Recently China published its guideline for biosimilar approval in 2015. 
This article summarizes the regulatory requirements for approval of biosimilars in India, Europe, Brazil, and China. These countries require 
comparability exercise of a biosimilar with reference biological product for generating comparative analytical, non-clinical and clinical data (usually 
one or two phase 1 and phase 3 comparative studies). A case study of infliximab biosimilar approval in India, Brazil and Europe has also been 
included.  
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European nations are the biggest market for biosimilars, followed by 
Asia-Pacific countries with, China and India expected to grow at the 
fastest rate. Brazil is also poised to register high growth rate in next 
five years [1, 2]. The first opinion on biosimilars was published by the 
European Union (EU) in early 2000s, post which many guidelines 
covering individual biosimilars were released and revised from time to 
time. [3]. Around the same time, the US Food and Drug Administration 
(FDA) started discussing the concept of so-called “follow-on biologics” 
[4] with first draft guidance published in February 2012 and updated in 
2015. India, Brazil and China and Brazil released their biosimilar 
guidance in 2010, 2012 and 2015 respectively.  
Unlike small chemical molecules, with defined and entirely 
reproducible structure, proteins are more complex and unlikely to 
be structurally identical to a reference product. Many potential 
differences in protein structure can arise. Even minor structural 
differences (changes in glycosylation patterns) can significantly 
affect a protein’s safety and effectiveness and hence it is important 
to evaluate these differences [5]. 
Since biosimilars are not “generic medicines”, many characteristics 
associated with the authorization process do not apply. 
Manufacturing biosimilars are highly complex and expensive apart 
from the unique knowledge required to establish the relevant cell 
clone expressing the protein [5]. The current analytical methodology 
may not be able to detect all relevant structural and functional 
differences between two protein products [6]. Also, there may be an 
incomplete understanding of the relationship between a product’s 
structural attributes and its clinical performance.  
The data derived from analytical studies, animal studies, and clinical 
studies are required to demonstrate bio-similarity because 
bioavailability/bioequivalence studies alone would not conclude the 
bio-similarity is owing to the complex nature of the biotechnology-
derived products [5]. 
Whether the ‘biosimilar’ approach would be applicable to an 
individual biological medicinal product depends on the state of the 
art of analytical procedures, the manufacturing processes employed, 
as well as clinical and regulatory experiences, e. g. as regards the 
possibility to identify comparability margins, availability of sensitive 
clinical endpoints and model conditions etc [5]. 
The posology and route of administration of the biosimilar should be 
similar to the reference medicinal product. Deviations from the 
reference product as regards formulation or excipients require 
justification or further studies [5, 7]. 
A similar step-by-step development process for biosimilars 
followed across geographies 
The development of a biosimilar involves stepwise comparability 
exercise(s) beginning with an evaluation of the quality 
characteristics of biosimilar and reference biological product. 
Establishing similarity between biosimilar and reference biological 
requires comparison of quality characteristics that will lead to the 
reduction of non-clinical and clinical data needed for the approval 
process. If relevant differences are found in the quality, non-clinical 
or clinical studies, the product will not likely qualify as a biosimilar, 
and a more extensive non-clinical and clinical data set will likely be 
required to support its application for licensure. The extent and 
nature of the non-clinical and clinical studies to be performed 
depend on the level of evidence obtained in the previous step(s) 
including the robustness of the physicochemical, biological and non-
clinical In vitro data. The goal is to exclude differences between the 
biosimilar and the reference medicinal product. Therefore, studies 
should be sensitive enough with regard to design, population, 
endpoints, and conduct to detect such differences [8]. 
Step-wise approach 
a. Analytical, quality comparison/characterization 
• Manufacturing process 
• Product characterization 
• Structural and physicochemical properties 
• Biological activity 
• Immunological properties 
• Purity and impurities 
• Stability 
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• Quality comparability study 
b. Non-clinical studies (Comparative) 
• In vitro studies 
• In vivo studies 
c. Clinical studies (Comparative) 
• Pharmacokinetic (PK) studies 
• Pharmacodynamics (PD) studies 
• Confirmatory safety and efficacy studies 
• Safety and immunogenicity data 
Data requirement (including local clinical data) 
• Biosimilars need to establish similarity to the reference product 
in terms of quality, non-clinical and clinical studies. 
• Analytical and non-clinical data requirement are similar across 
countries. 
• Local subject participation is required in local or global phase I 
and phase III study. Local Phase I studies may be waived off in 
certain geographies at the discretion of the regulatory authority. 
• Since local participation is required in all countries, so Phase III 
trial should be global and multi-centric. 
• There is a need to develop a robust post-marketing surveillance 
plan to allay safety/immunogenicity concerns. 
Reference product requirement 
Reference product should be registered in a country where the 
approval for a biosimilar is sought. Reference product registered in a 
different country may be used with bridging data comparing 
biosimilar, country registered reference product and out-site 
country registered reference product used in comparability exercise. 
Clinical trials initiation and filing of biosimilar application 
Clinical trials can be initiated at any time irrespective of patent 
expiry. This provision is available in many countries and is similar to 
BOLAR provision in US [§ 271(e) (1) exemption from infringement if 
patented reference product is used for generating data for 
submitting to regulatory agency]. Biosimilar application can be filed 
only after the expiry of regulatory/data exclusivity. In Europe, the 
application can be filed after eight years of data exclusivity; 
however, approval can happen after ten years of exclusivity (8+2 
exclusivity). There is no data exclusivity in India and Brazil. 
However, a biosimilar can only be approved or launched after the 
expiry of patent and regulatory exclusivity. Approval time for 
biosimilar usually ranges from 12-20 mo. To be among the early 
entrants in the main markets, clinical development of biosimilars 
should be completed at least two years before the expiry of the 
patent, taking into consideration time for dossier preparation and 
regulatory review. 
Indication extrapolation 
Extrapolation to other indications is acceptable based on scientific 
justification. By submitting data for one lead indication, approval for 
other approved indications (extrapolation) of reference product is 
possible if scientific justification is provided. 
Interchangeability 
No provision of interchangeability in guidelines of most geographies. 
In EU, no automatic substitution and decision for interchangeability 
are left to the member state. 
India-biosimilar regulatory requirement [9-12] 
Guideline 
Regulatory requirements for marketing authorization of similar 
biologic in India were released in 2012 and require extensive 
quality/analytical comparative data in addition to abridged 
clinical/non-clinical studies are required for biosimilar approval.  
Data requirement 
Analytical and quality characterization data 
Comparability according to critical quality attributes of product 
including physicochemical properties, biological activity, 
immunological properties, functional assays, purity (process and 
product-related impurities, etc.), contamination, strength, and 
content. 
Non-clinical studies 
• In vitro studies: e. g. cell-based bioassay (e. g., cell proliferation 
assays or receptor binding assays) 
• In vivo studies: PD activity, immunogenicity, at least one repeat 
dose toxicity study, local tolerance (may be part of repeat dose 
toxicity study); safety pharmacology, reproductive toxicity, 
mutagenicity, and carcinogenicity studies are not required unless 
warranted by repeat dose toxicity studies. 
Clinical studies 
• Phase I: Comparative PK (Pharmacokinetics) and PD 
(pharmacodynamics) studies; PK/PD relationship may be evaluated. 
PD evaluation can also be done as part of Phase III study (usually 1 
or 2 Clinical Trails (CTs) depending on indications) 
• Phase III: Comparative efficacy and safety/immunogenicity 
study are essential (usually 1 or 2 CTs, depending on a number of 
indications and safety profile). 
• Equivalence design study is preferred. 
• Non-inferiority design needs to be justified. 
• Safety and efficacy CT can be waived off if comparable quality, 
non-clinical and clinical PK-PD data with post-marketing risk 
management plan is provided (cannot be waived if there is no 
reliable and validated PD marker). 
• Post-marketing: Safety and immunogenicity data must be 
submitted  
Extrapolation to other indication 
May be possible if the same Mechanism of Action (MOA)/receptors for 
indications (with similar safety, efficacy, preclinical and quality data) 
Reference product requirements 
• Reference biologic should be licensed in India and should be 
innovator product. 
• If reference biologic is not marketed in India, then it should be 
licensed and widely marketed for four years post approval in 
innovator jurisdiction in a country with the well-established 
regulatory framework. 
• In case no medicine or only palliative therapy is available or in 
the case of national healthcare emergency, this period of 4 y may be 
reduced or waived. 
Interchangeability 
Not mentioned in the guideline. 
Europe-biosimilar regulatory requirement [3, 13-15] 
Guidelines 
• EU Guideline on similar biological medicinal products 
• EU Guideline on similar biological medicinal products 
containing biotechnology-derived proteins as active substance: 
quality issues (revision 1) 
• EU Guideline on similar biological medicinal products 
containing biotechnology-derived proteins as active substance: 
non-clinical and clinical issues 
Similar Biological Medicinal product is a biological medicinal 
product that is similar to the active substance of an already 
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authorized biological medicinal product (reference medicinal 
product) in European Economic Area (EEA). The similarity to 
reference medicinal product in terms of quality characteristics, 
biological activity, safety and efficacy based on a comprehensive 
comparability exercise must be established. Comparative analytical 
data along with the clinical and non-clinical data is required to 
establish the similarity.  
Data requirement 
Analytical, quality characterization data 
Comprehensive analyses of biosimilar and reference product. Any 
differences detected in quality attributes will have to be appropriately 
justified concerning their potential impact on safety and efficacy. 
Non-clinical data 
• Phase 1: Comparative PK/PD studies 
• Usually 1 or 2 CTs depending on indications 
• Phase 3: Confirmatory Safety and Efficacy Studies 
• Usually 1 or 2 CTs, depending on a number of indications and 
safety profile. 
• In general, an equivalence design should be used. 
• The non-inferiority design may be acceptable if justified on the 
basis of a strong scientific rationale. 
• Post-marketing: Safety and immunogenicity data 
Extrapolation to other indication 
• Extrapolation to other indications needs to be scientifically 
justified 
• Additional data required  
• If the drug acts on multiple active sites/receptors in different 
indications 
• Immunogenicity and safety are different  
• If studied indication is not sensitive in detecting differences in 
all aspects of efficacy and safety 
The infliximab biosimilar (Remsima) was approved by EMA 
(European Medicines Agency) for all indications for reference 
biologic on the basis of submitted clinical data for rheumatoid 
arthritis and ankylosing spondylitis. 
Reference product requirement 
• Must be authorized in European Economic Area (EEA) 
• In the case of non-EEA authorized comparator, bridging data 
comparing all three products including analytical studies with 
clinical and non-clinical data should be submitted (proposed 
biosimilar, EEA-authorized reference product and not EEA-
authorized comparator).  
Interchangeability 
• Interchangeability assessment is left to member states. 
• In EU countries, treatment decisions to treat patients is left to 
the physicians and patients to avoid “automatic substitution.” 
• France Law (2014) states that a biosimilar may be dispensed 
only as an initial treatment to a new, or “naive” patient, and 
only if physician states that prescribed biologic is “non-
substitutable.” 
• In the case of substitution, records are maintained by the 
pharmacists. 
European biosimilar marketing authorization summary 
Out of 29 Marketing Authorization Applications (MAA) filed, 21were 
approved, one was rejected, and seven were withdrawn by the 
applicant. Out of 21 approved biosimilars, two were voluntarily 
withdrawn by the applicant (fig. 1).  
 
 
Fig. 1: Market authorization summary of Europe 
 
Brazil-biosimilar regulatory summary [16, 17] 
Guidelines 
• ANVISA (National Health Surveillance Agency) Guideline on 
Biosimilar (Board Resolution-RDC No. 55 OF 16 DECEMBER 2010) 
Biosimilar regulatory guideline for Brazil was released in 2010 and 
is based on WHO and EU biosimilar guidelines. Follow-on biological 
product which is comparable to reference biological with respect to 
quality, non-clinical and clinical parameters in terms of quality, 
efficacy, and safety. 
Data requirement 
Analytical, quality characterization data 
Biological and physicochemical characterization related to quality 
attributes, purity, and impurity profile, with discussion of potential 
impact on quality, safety, and efficacy. 
Non-clinical studies data 
• In vitro studies 
• In vivo studies: Pharmacodynamics studies and studies of 
cumulative toxicity (repeat dose) including parameters 
characterizing kinetics of toxicity 
Clinical studies data 
• Phase I: PK and PD studies; can be a combined study (usually 1 or 
2 CTs depending on indications) 
• Phase III: comparative clinical safety and efficacy pivotal studies 
(usually 1 or 2 CTs, depending on number of indications and 
safety profile) 
• Post-marketing: Safety and immunogenicity data 
Extrapolation to other indication 
• MOA and receptors involved for different indications are same.  
• Safety and Immunogenicity are sufficiently characterized. 
Reference product requirements 
• Reference product should be registered with ANVISA Brazil. 
• Non-Brazil reference product needs to be registered by another 
regulatory authority which has similar criteria as ANVISA with 
full unrestricted access to registration information to ANVISA. 
Interchangeability 
Not mentioned in the guidelines. 
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China-biosimilar regulatory summary [18-20] 
Guidelines 
• Chinese guidance for the development, evaluation, license 
approval of biosimilars was released in 2015. 
Similar therapeutic biological product/biosimilar is similar to an 
authorized reference product in terms of quality, safety, and efficacy. 
Biosimilar should contain same active substance as the reference 
product, and differences such as different host cell and expression 
system should be justified. 
Data requirement 
Analytical, quality characterization data 
• Comparability in production processes, structural and functional 
characterization, physical and chemical properties, potency, purity. 
• Biosimilar drug should have a same amino acid sequence as the 
reference product. 
Non-clinical data 
• In vitro studies 
• In vivo studies: PK, PD, immunogenicity assessment, repeat 
dose toxicity studies and other toxicity studies should be 
conducted using same models and animal species as the 
reference product. 
Clinical data 
• Phase I: PK and PD study (usually 1 or 2 CTs depending on 
indications) 
• Phase III: Comparative efficacy and safety/immunogenicity 
study (usually 1 or 2 CTs depending on indications) 
• Post-marketing: Risk management plan, safety, and 
immunogenicity data 
Extrapolation to other indication 
Extrapolation of indications possible, which will be considered on a 
case-by-case basis and product specific based on appropriately 
selected indications which have been thoroughly studied in clinical 
trials. Safety and immunogenicity in relation to extrapolated 
indications should be sufficiently assessed. 
  
Table 1: A comparative summary of data submitted for approval of infliximab biosimilar in India, Brazil, and Europe 
Country/Data  India Europe Brazil  
Company Ranbaxy (sun pharmaceuticals)/Epirus 
Biopharmaceuticals 
Celltrion Celltrion 
Approval Date Mar 2014 (approval)/Nov 2014 (launch) 10 Sep 2013 April 27, 2015 
Reference 
Biologic  
Remicade/Janssen Biologics  
Analytical Data Extensive bio-analytical and physicochemical comparison 
of infliximab biosimilar and Remicade including full side-
by-side characterization of all Critical Quality Attributes 
(CQAs). 
An extensive product 
characterization exercise 
was conducted, to 
elucidate:  
1. Primary, secondary and 






4. Charged isoforms 
5. Purity and biological 
activity associated with CT-
P13 (Remsima) 
Celltrion submitted same analytical 
data related to manufacturing, 
quality control, and therapeutic 
experimentation report as filed 





Target binding studies 
 
33 in vitro studies including 
comparative binding 
affinity, apoptotic effects, 
human tissues cross-
reactivity, etc. 
Same as filed before EMA 
In vivo 
1. Two single dose toxicity in Swiss albino mice and Wistar 
rats;  
2. Two repeat dose toxicity in Wistar rats and New Zealand 
White Rabbits 
1. Two weeks repeat dose 
toxicity studies in rats  
2. One dose range finding 
study 
Same as filed before EMA 
Clinical Data Phase I study 
Intravenous dose study (in the United Kingdom) in 84 
healthy volunteers to compare pharmacokinetics, safety, 
tolerability and immunogenicity of infliximab biosimilar 
(n=43) with Remicade (n=41) with a 12-week follow-up 
period 
1. 54 w study: PK at 22 and 
30 w; long-term efficacy, 
PK and safety up to 54 w 
2. 102 w study: PK at 0, 2 
and 6 w; PD, efficacy, and 
safety up to 102 w 
Same as filed before EMA 
Phase III study 
One Phase III randomized, double-blind, active comparator 
study (in India) to compare efficacy and safety of infliximab 
biosimilar (n=127) with Remicade (62) with severe, active 
rheumatoid arthritis on stable doses of methotrexate in 
189 patients with rheumatoid arthritis taking methotrexate 
One comparative 
equivalence study of 54 w 
duration 
Efficacy at 30 and 54 w; 
long-term safety, 
immunogenicity up to 54 w 
Same as filed before EMA 
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Reference product requirement 
• China FDA approved reference product. Reference product can 
be pending for cFDA approval during early stages of biosimilar 
development process, but must be approved by cFDA when 
comparative clinical studies are conducted. 
• Companies cannot use an approved biosimilar as reference drug. 
Interchangeability 
The guideline does not mention any concept of interchangeability 
(table 1). 
CONCLUSION 
The standard generic approach (demonstration of bioequivalence 
with a reference medicinal product by appropriate bioavailability/ 
bioequivalence studies) which applies to most chemically-derived 
medicinal products is in principle not appropriate to 
biological/biotechnology-derived products due to their complexity. 
For approval of a biosimilar product, guidelines in various countries 
provide abbreviated approval pathway involving step-wise 
comparability exercise of a biosimilar with reference biological 
product which requires the generation of comparative analytical, 
non-clinical and clinical data (usually one or two phase I and phase 3 
comparative studies). The scientific principles of such a biosimilar 
comparability exercise are based on those applied for evaluation of 
the impact of changes in manufacturing process of a biological 
medicinal product. The amount of data required for biosimilar 
approval is more than that for generic small molecule chemical 
product approval and less than that for reference biological product. 
Analytical and non-clinical data requirement are similar across 
countries. Local subject participation is required in local or global 
phase I and phase III study. Local Phase I studies may be waived off 
in certain geographies like India and Brazil at the discretion of the 
regulatory authority. Since local participation is required in all 
countries, so Phase III trial should be global and multi-centric. There 
is a need to develop a robust post-marketing surveillance plan to 
allay safety/immunogenicity concerns. 
Reference product used in comparability exercise should be 
registered in a country where the approval for a biosimilar is sought. 
However, reference product registered in a different country may be 
used with bridging data. 
Clinical trials can be initiated at any time irrespective of patent 
expiry. This provision is available in many countries and is similar to 
BOLAR provision in US [§ 271(e) (1) exemption from infringement if 
patented reference product is used for generating data for 
submitting to regulatory agency]. Biosimilar application can be filed 
after the expiry of regulatory/data exclusivity. However, a biosimilar 
can only be approved or launched after the expiry of patent and 
regulatory exclusivity. 
By submitting data for one lead indication, approval for other 
approved indications (extrapolation) of reference product is 
possible if scientific justification is provided. There is no provision of 
interchangeability in guidelines of most of the geographies. In EU, no 
automatic substitution and decision for interchangeability are left to 
the member country. 
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